Phase I Trial of Fludarabine and Methoxyamine (TRC102) for Relapsed or Refractory Hematologic Malignancies
Phase of Trial: Phase I
Latest Information Update: 13 Nov 2017
At a glance
- Drugs TRC 102 (Primary) ; Fludarabine
- Indications Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Haematological malignancies; Hodgkin's disease; Multiple myeloma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 13 Nov 2017 Results presented in a TRACON Pharmaceuticals Media Release.
- 13 Nov 2017 According to a TRACON Pharmaceuticals media release, results were published in the journal Oncotarget (Volume 8).